{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:06:56Z","timestamp":1791461216139,"version":"4.3.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>mRNA-1283 is an investigational coronavirus disease 2019 (COVID-19) mRNA vaccine encoding the receptor-binding and N-terminal domains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in contrast to the original mRNA-1273 vaccine, which encodes the full-length spike protein.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A phase 2a, dose-ranging, observer-blind, randomized study conducted in adults (aged \u226518 years) previously vaccinated with mRNA-1273 evaluated the safety and immunogenicity of a single dose of mRNA-1283 (2.5, 5, and 10\u2005\u00b5g) and its bivalent formulation, mRNA-1283.211 (5 and 10\u2005\u00b5g; encoding original SARS-CoV-2 and Beta) against the comparator mRNA-1273 vaccine, 50\u2005\u00b5g (part A). A subsequent, open-label study (part B) evaluated the safety and immunogenicity of a monovalent Omicron BA.1 vaccine, mRNA-1283.529 (5 and 10\u2005\u00b5g).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 340 participants were randomized in part A, and 200 participants were enrolled in part B. All dose levels of mRNA-1283 vaccines were well tolerated and increased the neutralizing antibody (nAb) responses at day 29 compared to baseline against SARS-CoV-2 D614G and Beta. The nAb responses elicited by mRNA-1283 were higher than those elicited by mRNA-1273. mRNA-1283.529 (part B) increased nAb at day 29 against Omicron BA.1. Antibody responses remained detectable for a year postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>mRNA-1283 was well tolerated and exhibited improved immunogenicity compared to mRNA-1273.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT05137236.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf022","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:18:46Z","timestamp":1736529526000},"page":"e754-e763","source":"Crossref","is-referenced-by-count":15,"title":["Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-1158","authenticated-orcid":false,"given":"Spyros","family":"Chalkias","sequence":"first","affiliation":[{"name":"Clinical Development, Infectious Diseases, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antionette","family":"Pragalos","sequence":"additional","affiliation":[{"name":"CTI Clinical Trial and Consulting Services , Covington, Kentucky ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebayo","family":"Akinsola","sequence":"additional","affiliation":[{"name":"Tekton Research , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Berman","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Inc , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Ampajwala","sequence":"additional","affiliation":[{"name":"Advanced Care Research Centers (ACRC) Trials , Plano, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Meyer","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research , Lincoln, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Schoch","sequence":"additional","affiliation":[{"name":"Clinical Operations, Infectious Disease, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Biostatistics, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna D","family":"Paila","sequence":"additional","affiliation":[{"name":"Clinical Biomarkers, Infectious Disease, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Deng","sequence":"additional","affiliation":[{"name":"Biostatistics, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[{"name":"Biostatistics, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"de Windt","sequence":"additional","affiliation":[{"name":"Clinical Safety, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Edwards","sequence":"additional","affiliation":[{"name":"Infectious Disease, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Miller","sequence":"additional","affiliation":[{"name":"Research and Development, Infectious Disease, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Research and Development, Infectious Disease, Moderna, Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"2025041514243460800_jiaf022-B1","doi-asserted-by":"crossref","first-page":"e000104","DOI":"10.1136\/bmjmed-2021-000104","article-title":"Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe COVID-19 outcomes in a nationwide mass vaccination setting: cohort study","volume":"1","author":"Bouillon","year":"2022","journal-title":"BMJ Med"},{"key":"2025041514243460800_jiaf022-B2","doi-asserted-by":"crossref","first-page":"e068848","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"BMJ"},{"key":"2025041514243460800_jiaf022-B3","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"},{"key":"2025041514243460800_jiaf022-B4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"2025041514243460800_jiaf022-B5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/14760584.2023.2232851","article-title":"Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era","volume":"22","author":"Pather","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2025041514243460800_jiaf022-B6","doi-asserted-by":"crossref","first-page":"eadf4100","DOI":"10.1126\/scitranslmed.adf4100","article-title":"Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2","volume":"15","author":"Stewart-Jones","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025041514243460800_jiaf022-B7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/vaccines9091033","article-title":"Challenges of storage and stability of mRNA-based COVID-19 vaccines","volume":"9","author":"Uddin","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025041514243460800_jiaf022-B8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025041514243460800_jiaf022-B9","doi-asserted-by":"crossref","first-page":"2190690","DOI":"10.1080\/21645515.2023.2190690","article-title":"Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults","volume":"19","author":"Yassini","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2025041514243460800_jiaf022-B10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025041514243460800_jiaf022-B11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","article-title":"Factors affecting stability of RNA\u2014temperature, length, concentration, pH, and buffering species","volume":"113","author":"Chheda","year":"2024","journal-title":"J Pharm Sci"},{"key":"2025041514243460800_jiaf022-B12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent Omicron-containing booster vaccine against COVID-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"2025041514243460800_jiaf022-B13","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41591-023-02517-y","article-title":"Original SARS-CoV-2 monovalent and Omicron BA.4\/BA.5 bivalent COVID-19 mRNA vaccines: phase 2\/3 trial interim results","volume":"29","author":"Chalkias","year":"2023","journal-title":"Nat Med"},{"key":"2025041514243460800_jiaf022-B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"2025041514243460800_jiaf022-B15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025041514243460800_jiaf022-B16","author":"Moderna US, Inc"},{"key":"2025041514243460800_jiaf022-B17","author":"Pfizer Inc"},{"key":"2025041514243460800_jiaf022-B18","first-page":"CD015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041514243460800_jiaf022-B19","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"2025041514243460800_jiaf022-B20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"2025041514243460800_jiaf022-B21","doi-asserted-by":"crossref","first-page":"e75228","DOI":"10.7554\/eLife.75228","article-title":"Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike","volume":"11","author":"Crowley","year":"2022","journal-title":"Elife"},{"key":"2025041514243460800_jiaf022-B22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1473-3099(23)00295-5","article-title":"Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial","volume":"23","author":"Lee","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf022\/61410126\/jiaf022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/4\/e754\/61410126\/jiaf022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/4\/e754\/61410126\/jiaf022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:52:50Z","timestamp":1744728770000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/4\/e754\/7951371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,10]]},"published-print":{"date-parts":[[2025,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf022","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,15]]},"published":{"date-parts":[[2025,1,10]]}}}